JPWO2021171257A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021171257A5 JPWO2021171257A5 JP2022551247A JP2022551247A JPWO2021171257A5 JP WO2021171257 A5 JPWO2021171257 A5 JP WO2021171257A5 JP 2022551247 A JP2022551247 A JP 2022551247A JP 2022551247 A JP2022551247 A JP 2022551247A JP WO2021171257 A5 JPWO2021171257 A5 JP WO2021171257A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- antigen
- binding portion
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982852P | 2020-02-28 | 2020-02-28 | |
| US62/982,852 | 2020-02-28 | ||
| PCT/IB2021/051636 WO2021171257A1 (en) | 2020-02-28 | 2021-02-26 | Anti-axl antibodies and compositions |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023515821A JP2023515821A (ja) | 2023-04-14 |
| JP2023515821A5 JP2023515821A5 (https=) | 2024-03-01 |
| JPWO2021171257A5 true JPWO2021171257A5 (https=) | 2024-03-01 |
| JP7748377B2 JP7748377B2 (ja) | 2025-10-02 |
Family
ID=75426640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551247A Active JP7748377B2 (ja) | 2020-02-28 | 2021-02-26 | 抗ａｘｌ抗体及び組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11807688B2 (https=) |
| EP (1) | EP4110824A1 (https=) |
| JP (1) | JP7748377B2 (https=) |
| KR (1) | KR20220148237A (https=) |
| CN (1) | CN115210263A (https=) |
| AR (1) | AR121441A1 (https=) |
| AU (1) | AU2021225490B2 (https=) |
| BR (1) | BR112022015977A2 (https=) |
| CA (1) | CA3170975A1 (https=) |
| CL (1) | CL2022002259A1 (https=) |
| CO (1) | CO2022012159A2 (https=) |
| IL (1) | IL295596A (https=) |
| MX (1) | MX2022010670A (https=) |
| MY (1) | MY209381A (https=) |
| PE (1) | PE20221783A1 (https=) |
| PH (1) | PH12022552041A1 (https=) |
| WO (1) | WO2021171257A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026001894A1 (zh) * | 2024-06-24 | 2026-01-02 | 上海医药集团生物治疗技术有限公司 | 靶向axl的嵌合抗原受体及其用途 |
| CN119591720B (zh) * | 2024-11-28 | 2026-02-10 | 北京大学深圳研究生院 | 抗人axl抗体、基因及其应用 |
| CN119912586B (zh) * | 2024-12-31 | 2025-09-30 | 四川省肿瘤医院 | 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| CA2706549A1 (en) * | 2007-11-15 | 2009-05-22 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| BRPI1013428A2 (pt) * | 2009-05-11 | 2019-07-02 | U3 Pharma Gmbh | anticorpos humanizados para axl |
| BR112012027995A2 (pt) * | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| MX2015005757A (es) * | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| JP6931609B2 (ja) | 2014-12-18 | 2021-09-08 | ベルゲン テクノロジオーヴァーフォリング エイエス | 抗Ａｘｌアンタゴニスト抗体 |
| CN108368171A (zh) * | 2015-07-10 | 2018-08-03 | 根马布股份公司 | 用于癌症治疗的axl特异性抗体-药物缀合物 |
| PL3368572T3 (pl) * | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| TN2018000333A1 (en) * | 2016-04-12 | 2020-01-16 | Symphogen As | Anti-tim-3 antibodies and compositions |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CA3095986A1 (en) | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
-
2021
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en not_active Ceased
- 2021-02-26 AU AU2021225490A patent/AU2021225490B2/en active Active
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 PH PH1/2022/552041A patent/PH12022552041A1/en unknown
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-02-26 MY MYPI2022004441A patent/MY209381A/en unknown
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko active Pending
- 2021-02-26 JP JP2022551247A patent/JP7748377B2/ja active Active
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6959970B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2024109885A (ja) | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 | |
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| CA3089254C (en) | Bispecific antibody and uses thereof | |
| CN105492024A (zh) | Met结合剂及其用途 | |
| JP2017534259A5 (https=) | ||
| JP2022551662A (ja) | Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体 | |
| JP2008508858A5 (https=) | ||
| CA2816358A1 (en) | Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy | |
| BR112021001509A2 (pt) | agente terapêutico para um tumor de cérebro metastásico | |
| CN106714822A (zh) | 用于治疗癌症的组合治疗 | |
| JPWO2019152705A5 (https=) | ||
| JPWO2021044005A5 (https=) | ||
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| CN105017421B (zh) | 一种抗her2双特异性抗体及其制备方法与应用 | |
| WO2022089644A1 (zh) | 靶向cd5的全人源抗体、全人源嵌合抗原受体(car)及其应用 | |
| CN115210263A (zh) | 抗axl抗体和组合物 | |
| CN114685675B (zh) | 双特异性抗体及其在治疗癌症中的用途 | |
| JP2026032010A (ja) | 二重特異性抗体及びその応用 | |
| JPWO2021171257A5 (https=) | ||
| CN112703038B (zh) | 靶向CD38和TGF-β的抗癌组合疗法 | |
| JPWO2021209495A5 (https=) | ||
| JP2023179400A (ja) | 抗メソテリン抗体、抗ｃｄ３抗体又は抗ｅｇｆｒ抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用 | |
| TWI820058B (zh) | 對表皮生長因子受體具有增加的親和性之抗體及其衍生之片段 |